Artificial intelligence in the diagnosis and prognosis of myelodysplastic syndrome

Artificial intelligence in the diagnosis and prognosis of myelodysplastic syndrome.

A new personalised medicine algorithm can calculate the risk of progression of myelodysplastic syndromes, taking into account the patient’s gender and age, which are key factors in the prognosis of these syndromes.

This is the result of a study coordinated by Humanitas within the European consortium GenoMed4All and recently published in the Lancet Haematology.

The algorithm was developed by a group of researchers led by Matteo Della Porta, Head of the Leukaemia and Myelodysplasia Unit at the IRCCS Humanitas Clinical Institute in Milan.

Artificial intelligence (AI) played a crucial role in the retrospective analysis of the data and, thanks to the collaboration with data scientists from the Humanitas AI Centre, the researchers developed algorithms capable of applying these two innovative prognostic models to individual patients.

Thanks to this study, by entering the patient’s data into an online platform, the doctor can now obtain a more accurate prognosis for each individual patient.

The prognosis is then compared with traditional systems (International Prognostic Scoring System – IPSS-R), which only use disease-related parameters.

The new algorithm can therefore calculate whether the patient is at risk of developing a more aggressive form of the disease, identify potential therapies of varying intensity and determine when to start treatment.